Curis, Inc. Reports Financial Highlights and Updates on Emavusertib Development in Q4 2025 Curis, Inc. shares its Q4 2025 financial results and updates on emavusertib trials, showcasing significant advancements in lymphoma treatment strategies and financial recovery.

Curis, Inc. Reports Financial Highlights and Updates on Emavusertib Development in Q4 2025 #United_States #healthcare #Lexington #Curis #emavusertib

Curis, Inc. Secures $80.8 Million Through Successful Private Placement Financing Curis, Inc., a biotechnology firm, has successfully closed a private placement financing, raising up to $80.8 million to advance drug development.

Curis, Inc. Secures $80.8 Million Through Successful Private Placement Financing #United_States #Lexington #Private_Placement #emavusertib #Curis_Inc

Curis Secures $80.8 Million Through Private Placement Financing for Future Development Curis, Inc. has announced a private placement expected to deliver up to $80.8 million. The financing aims to support research and development initiatives for its oncology drug, emavusertib.

Curis Secures $80.8 Million Through Private Placement Financing for Future Development #United_States #biotechnology #Lexington #Curis #emavusertib

Curis Announces Promising Results from Frontline AML Triplet Study Curis, Inc. reports updated, encouraging data from its ongoing frontline AML triplet study, showcasing potential breakthroughs in treatment options for patients.

Curis Announces Promising Results from Frontline AML Triplet Study #United_States #AML #Lexington #Curis #emavusertib

Curis Inc. Unveils Exciting Findings at the 30th Annual SNO Meeting Curis, Inc. will present groundbreaking clinical and preclinical data on emavusertib at the upcoming 30th SNO Meeting in November 2025.

Curis Inc. Unveils Exciting Findings at the 30th Annual SNO Meeting #United_States #Lexington #Curis #emavusertib #SNO_Meeting

Curis Reports Promising Third Quarter 2025 Business Updates and Future Prospects Curis, Inc. announces its third-quarter financial results, showcasing progress in clinical studies and ongoing developments for emavusertib in treating multiple cancers.

Curis Reports Promising Third Quarter 2025 Business Updates and Future Prospects #USA #Clinical_Trials #Lexington #Curis #emavusertib

Curis Inc. Announces Inducement Grants to New Employees Under NASDAQ Guidelines Curis, Inc. has reported the grant of stock options to new employees in compliance with NASDAQ regulations, enhancing its workforce for future growth.

Curis Inc. Announces Inducement Grants to New Employees Under NASDAQ Guidelines #United_States #NASDAQ #Lexington #emavusertib #Curis_Inc.

Curis, Inc. to Showcase Innovations at Healthcare Conferences in September 2025 Curis, Inc. is gearing up for major healthcare conferences this September to discuss its oral small molecule IRAK4 inhibitor, emavusertib. CEO James Dentzer will present insights on advancements.

Curis, Inc. to Showcase Innovations at Healthcare Conferences in September 2025 #USA #healthcare #Lexington #Curis #emavusertib

Curis Shares Encouraging Progress in Second Quarter 2025 Updates Curis, Inc. highlights positive developments in its ongoing clinical studies in its latest business update, paving the way for future treatments.

Curis Shares Encouraging Progress in Second Quarter 2025 Updates #United_States #Clinical_Trials #Lexington #Curis #emavusertib

Curis, Inc. Approves Inducement Stock Options for New CMO Dr. Ahmed Hamdy Curis, Inc. has announced the approval of inducement stock options for Dr. Ahmed Hamdy, its new Chief Medical Officer, to enhance talent acquisition.

Curis, Inc. Approves Inducement Stock Options for New CMO Dr. Ahmed Hamdy #USA #Lexington #Curis #emavusertib #Dr._Ahmed_Hamdy

SOHO Insider Emavusertib Shows Promise in High-Risk MDS Emavusertib yields remissions in high-risk MDS with spliceosome mutations, per ASH 2023 TakeAim trial data."

Preliminary TakeAim data shows promise of #emavusertib in higher-risk #MDS #ASH24 #ASHthrowback

sohoinsider.com/meetings-con...

Curis Provides Business Update and Financial Results for Q4 2024 Curis, Inc. has announced its fourth quarter 2024 business update, paving the way for accelerated drug approval discussions in the US and EU.

Curis Provides Business Update and Financial Results for Q4 2024 #USA #Lexington #Curis #emavusertib #PCNSL

Curis Unveils Groundbreaking Data from the TakeAim Leukemia Clinical Trial Curis, Inc. shares promising results from the TakeAim Leukemia study on emavusertib, showing substantial effectiveness in R/R AML patients.

Curis Unveils Groundbreaking Data from the TakeAim Leukemia Clinical Trial #United_States #AML #Lexington #Curis #emavusertib